Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8907523 | 1.00 | DDB1 (0.46) | DDB1CRBNALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL9204508 | 0.85 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL10785422 | 0.83 | DDB1 (0.42) | DDB1CRBNALDH1A1 | |
| SCHEMBL1150916 | 0.83 | DDB1 (0.42) | DDB1CRBNALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL2499403 | 0.83 | DDB1 (0.42) | DDB1CRBNALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL2084722 | 0.82 | ALDH1A1 (0.48) | DDB1CRBNALDH1A1KMT2A | |
| SCHEMBL11435272 | 0.82 | DDB1 (0.41) | DDB1CRBNALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL7378927 | 0.82 | DDB1 (0.41) | DDB1CRBNALDH1A1 | |
| SCHEMBL10572588 | 0.82 | DDB1 (0.41) | DDB1CRBNALDH1A1 | |
| SCHEMBL1150970 | 0.81 | DDB1 (0.41) | DDB1CRBNALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493472-B2 | Substituted benzoxazoles | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-15 | — | — | US | disclosed |
| US-20160137647-A1 | SUBSTITUTED BENZOXAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-19 | — | — | US | disclosed |
| US-20160108027-A1 | SUBSTITUTED BENZOXAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-04-21 | — | — | US | disclosed |
| EP-1961750-B1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO CO LTD (JP) | 2013-09-18 | — | — | EP | disclosed |
| US-20130065882-A1 | VLA-4 inhibitory drug | MACHINAGA NOBUO (JP) | 2013-03-14 | — | — | US | disclosed |
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-06-21 | — | — | US | disclosed |
| US-8129366-B2 | VLA-4 inhibitory drug | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20080300231-A1 | Antibacterial amide macrocycles VI | BAYER HEALTHCARE AG (DE) | 2008-12-04 | — | — | US | disclosed |
| EP-1961750-A1 | VLA-4 INHIBITORY DRUG | Daiichi Sankyo Company, Limited (JP) | 2008-08-27 | — | — | EP | disclosed |
| US-5670515-A | TREATMENT OF THROMBOSIS, STROKE, CARDIAC INFARCT, INFLAMMATION, AND ARTERIOSCLEROSIS; ANTITUMOR AGENTS, WOUND HEALING AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1997-09-23 | — | — | US | disclosed |
| US-5658928-A | ANTICOAGULANTS, ANTIINFLAMMATORY AGENTS, ANTITUMOR AGENTS,WOUND HEALING AGENTS, OSTEOPOROSIS | HOFFMANN-LA ROCHE INC. (US) | 1997-08-19 | — | — | US | disclosed |
| US-5583146-A | Heterocyclic thrombin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-10 | — | — | US | disclosed |
| WO-1996035805-A2 | TRIPEPTIDYLPEPTIDASE INHIBITORS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1996-11-14 | — | — | WO | disclosed |
| US-5545658-A | FOR TREATMENT OR PROPHYLAXIS OF ILLNESSES WHICH ARE CAUSED BY THE BINDING OF ADHESIVE PROTEINS TO BLOOD PLATELETS AND BY BLOOD PLATELET AGGREGATION AND CELL-CELL ADHESION | HOFFMAN-LA ROCHE INC. (US) | 1996-08-13 | — | — | US | disclosed |
| US-5378712-A | Antithrombosis | Hoffmann-La Roche Inc (US) | 1995-01-03 | — | — | US | disclosed |
| EP-0243686-B1 | BETA-LACTAM COMPOUNDS, AND THEIR PRODUCTION | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1992-07-15 | — | — | EP | disclosed |
| US-5093328-A | Carbapenicillin antibiotics | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1992-03-03 | — | — | US | disclosed |
| US-4912231-A | Reacting a proline derivative with an aromatic nucleophile in presence of a Lewis acid catalyst | E. R. SQUIBB & SONS, INC. (US) | 1990-03-27 | — | — | US | disclosed |
| EP-0243686-A2 | Beta-lactam compounds, and their production | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1987-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300231-A1 | Antibacterial amide macrocycles VI | AADAC, AAAS, NOD2 | DDB1 2576/4885CRBN 4603/4885ALDH1A1 3434/4885 |
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | DDB1 3970/4885CRBN 2684/4885ALDH1A1 216/4885 |
| US-20130065882-A1 | VLA-4 inhibitory drug | VCAM1, ITGB4, ITGA4 | DDB1 4131/4885CRBN 2572/4885ALDH1A1 207/4885 |
| US-20160137647-A1 | SUBSTITUTED BENZOXAZOLES | TBXA2R, XDH, CYP4X1 | DDB1 1951/4885CRBN 1606/4885ALDH1A1 724/4885 |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | DDB1 3709/4885CRBN 3492/4885ALDH1A1 525/4885 |
| US-20160108027-A1 | SUBSTITUTED BENZOXAZOLES | TBXA2R, XDH, CYP4X1 | DDB1 1951/4885CRBN 1606/4885ALDH1A1 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.